# Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia

> **NCT02381548** · PHASE1 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 20 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Acute Myeloid Leukemia Post Cytotoxic Therapy
- Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive
- Myelodysplastic Syndrome
- Recurrent Adult Acute Myeloid Leukemia
- Recurrent Chronic Myeloid Leukemia, BCR-ABL1 Positive
- Refractory Acute Myeloid Leukemia
- Refractory Chronic Myeloid Leukemia, BCR-ABL1 Positive
- Secondary Acute Myeloid Leukemia

## Interventions

- **DRUG:** Adavosertib
- **DRUG:** Belinostat
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study

## Key facts

- **NCT ID:** NCT02381548
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-08-18
- **Primary completion:** 2018-05-23
- **Final completion:** 2018-05-23
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** Other - Adverse Events
- **Last updated:** 2026-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02381548

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02381548, "Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02381548. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*